DrugPatentWatch Database Preview
Novartis Pharms Company Profile
What is the competitive landscape for NOVARTIS PHARMS, and what generic alternatives to NOVARTIS PHARMS drugs are available?
NOVARTIS PHARMS has four approved drugs.
There are eight US patents protecting NOVARTIS PHARMS drugs.
There are one hundred and seventy-eight patent family members on NOVARTIS PHARMS drugs in fifty-three countries and twenty-five supplementary protection certificates in thirteen countries.
Summary for Novartis Pharms
| International Patents: | 178 |
| US Patents: | 8 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Novartis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | RX | Yes | No | Start Trial | Start Trial | |||||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-001 | Jul 7, 2015 | RX | Yes | No | 8,877,938*PED | Start Trial | Y | Start Trial | |||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-003 | Jul 7, 2015 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novartis Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,596,750 | Start Trial |
| Novartis Pharms | FEMARA | letrozole | TABLET;ORAL | 020726-001 | Jul 25, 1997 | 4,978,672 | Start Trial |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,465,504 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2006-03-02 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
International Patents for Novartis Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Croatia | P20180387 | Start Trial |
| Germany | 69716602 | Start Trial |
| Australia | 2014224198 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novartis Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1948158 | PA2016017 | Lithuania | Start Trial | PRODUCT NAME: SAKUBITRILAS/VALSARTANAS; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
| 0914118 | CA 2006 00035 | Denmark | Start Trial | |
| 0914118 | 300248 | Netherlands | Start Trial | 300248, 20170624, EXPIRES: 20210827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
